Christina Messiou1, Matthew Orton1, David J. Collins1, Veronica a Morgan1, Dorothy Mears2, Isabel Castellano2, Dionysis Papadatospastos3, Andre Brunetto3, Jooern Ang3, Helen Mann4, Jean Tessier4, Helen Young4, Stan Kaye3, Johann de Bono3, Martin O. Leach1, Nandita M. deSouza1
1CRUK & EPSRC Cancer Imaging Centre, Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 3Dept of Medicine, Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 4AstraZeneca, United Kingdom
The aim of this study was to establish within patient variability of DCE-MRI vs. DCE-CT in the same patients and compare their ability to measure changes in tumour blood flow and permeability in these patients when treated with the VEGFR tyrosine kinase inhibitor cediranib. Image parameters were reproducible-most were in the range 15-25%. The most reproducible parameter was DCE-MRI EF followed by DCE-MRI Ktrans and iAUC60, and DCE-CT PEI. DCE-MRI and DCE-CT were comparable when assessing changes from baseline in vascular physiology. There was generally a higher percentage change from baseline for parameters measuring area under the curve (iAUC60, PEI).